News NICE Approves Plegridy as RRMS Treatment Offered by NHS England NICE Approves Plegridy as RRMS Treatment Offered by NHS England by Marisa Wexler, MS | January 27, 2020 Share this article: Share article via email Copy article link The National Institute for Health Care and Excellence (NICE) in the U.K. issued its final decision, approving the inclusion of Plegridy (peginterferon beta-1a) to treatĀ relapsing-remitting multiple sclerosis (RRMS) in England within the National Health Service (NHS). This decision follows a cost-effectiveness review done in May 2018, in which NICE recommended BiogenāsĀ AvonexĀ andĀ Merck KGaA’sĀ RebifĀ (both interferon beta-1a),Ā NovartisāĀ ExtaviaĀ (interferon beta-1b), andĀ TevaāsĀ CopaxoneĀ (glatiramer acetate) and its generic Brabio (glatiramer acetate; marketed by Mylan) be available through the NHS as RRMS treatments. At the time, NICE said Plegridy, a Biogen therapy, would be assessed separately. Now, the final decision has been issued. “The cost-effectiveness estimates for peginterferon beta-1a compared with other treatments for relapsingāremitting multiple sclerosis, such as other beta interferons and glatiramer acetate, are in line with what NICE usually considers a cost-effective use of NHS resources,” NICE’sĀ recommendation states. “Therefore, peginterferon beta-1a can be recommended.” Plegridy is a form of interferon beta-1a (IFNb1a), a signaling molecule that helps to limit immune responses within the body. In people with MS, this can prevent the immune system from causing damage to neurons. In Plegridy, IFNb1a has been pegylated, a molecular alteration that allows IFNb1a to continue its effects in the body for longer, reducing the need for frequent dosing. In clinical trials, Plegridy has been shown to significantly decrease the rate of relapses compared to a placebo. The medicationĀ was previously approved for RRMS treatment in Scotland andĀ Wales. Guidance by NICE decides which treatments are funded by the NHSĀ in the U.K. and made available to patients. By law, theĀ NHS is obliged to fund medicines recommended by advisory bodies like NICE “We are pleased that NICE has approved Plegridy for people with relapsing-remitting MS,” David Martin, CEO of the MS Trust, said in a press release. The MS Trust aims to help people in the U.K. with MS, and to support access to MS specialist services. According to the press release, the MS Trust “contributed throughout the process” to obtain NICE’s approval of Plegridy. The Trust generally advocates for more effective therapies to be available to people with MS. “We were able to make a strong case to NICE thanks to those of you who told us about your experiences of taking this treatment, and the importance of having a greater choice of disease-modifying drugs,” Martin said. Plegridy is givenĀ by an injection under the skin (subcutaneous injection) on the stomach, upper arm, or thigh once every 14 days. Print This Page About the Author Marisa Wexler, MS Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America. Tags Biogen, England, MS Trust, National Institute for Health and Care Excellence, NICE, peginterferon beta-1a, Plegridy, RRMS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year
April 22, 2024 News by Margarida Maia, PhD Viatris launches low-dose Copaxone generic formulation in Canada
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients